U.S. and Italian researchers who studied 134 patients found that FDG-PET/MRI was more precise than FDG-PET/CT in assessing lymphadenopathy and certain tumors and proved to be more sensitive to hepatic and bony metastases. PET/MRI also tended to yield treatment-altering data, with seven patients beginning chemotherapy, five undergoing surgery and six avoiding biopsy, researchers reported in a radiology journal.

Related Summaries